Energy and Commerce clears meth bill
This article was originally published in The Tan Sheet
Executive Summary
The House Energy and Commerce Committee July 28 passes the Combat Methamphetamine Enhancement Act of 2009, H.R. 2923. The bill, which cleared the Energy and Commerce Subcommittee on Health days earlier, would require retailers of nonprescription pseudoephedrine products to self-certify compliance with existing Combat Meth regulations (1"The Tan Sheet" July 26, 2010). The legislation, which the Senate passed in S. 256 in June 2009, is expected to become law with support from both sides of the aisle and OTC and drug store trade groups
You may also be interested in...
Combat Meth Enhancement looks likely
Congressional staff expect the Combat Methamphetamine Enhancement Act to pass after the Senate and House agree to "minor technical corrections" in the legislation that requires retailers to comply with provisions of the Combat Methamphetamine Epidemic Act of 2006. Minor changes in the House bill passed Sept. 22 include tweaking phrasing, statutory citations, adding a statement to comply with the PAYGO Act and replacing 2009 with 2010 in the title. A Feinstein staffer said Senate members likely will approve the House version the week of Sept. 27. The bill requires retailers to self-certify compliance with Drug Enforcement Administration regulations concerning Combat Met Act retail sales provisions. It sets $5,000 penalties for noncompliance and prohibits distributors from delivering pseuodephedrine-containing OTCs to noncompliant stores. The Consumer Healthcare Products Association and the National Association of Chain Drugstores support the measure, which enhances regulations limiting sales of PSE without creating new restrictions on consumer access to the drugs (1"The Tan Sheet" Aug. 2, 2010, In Brief)
House Panel Gives Life To Enhancing Combat Meth Act
Legislation to bolster existing methamphetamine prevention regulations got a push from a House Energy and Commerce subcommittee July 22 after lying dormant for a year
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.